|
|
Profile
|
Delegates :
Makoto Yamamoto, Ph.D. |
|
Incorporated :
April 1 , 2022 |
Paid in Capital :
49 Million yen |
Employees :
人 |
Address :
Entrepreneur Lab, The University of Tokyo, Hongo7-3-1, Bunkyo-ku TOKYO
〒113-8485
|
TEL/FAX :
/ |
URL：
https://www.tkg-na.com/en |
Attachment :
|
Mission/Background :
TKG Therapeutic develops novel nucleic acid-based cancer immunotherapies and ultra-efficient nucleic acid synthesis technologies. Our lead program, TKG-001, is a hairpin nucleic acid STING agonist designed for tumor-selective innate immune activation via miRNA biomarkers. In parallel, we are advancing an automated synthesizer based on an immersion-type solid-phase method, reducing reagent use by >50%. Backed by Real Tech Fund, Mitsubishi Gas Chemical, and NEDO STS, TKG aims to accelerate partnerships and global expansion. |
|
Technology & Business
|
TKG Therapeutics is a University of Tokyo spin-off developing next-generation nucleic acid therapeutics and ultra-efficient nucleic acid synthesis technologies.
Drug Discovery: We are pioneering a novel class of cancer immunotherapy based on hairpin nucleic acids that form intracellular assemblies recognized by cGAS, activating the STING pathway to induce innate immunity. By leveraging miRNA biomarkers, our approach achieves tumor-selective immune activation with improved safety.
Synthesis Technology: We are developing an immersion-type solid-phase synthesis method (“Jabo-zuke method”) and an automated synthesizer prototype, aiming to reduce reagent consumption by more than 50%, enable large-scale production, and minimize environmental impact.
Keywords: Nucleic acid therapeutics, STING agonist, cGAS-STING pathway, miRNA biomarker, cancer immunotherapy, solid-phase synthesis, automated synthesizer, green chemistry.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
TKG-001
|
Preclinical
|
A tumor-selective STING agonist using hairpin nucleic acids. Selectivity achieved via miRNA overexpression in cancer cells.
|
Formulation optimization, non-clinical PoC, and co-development with pharma partners.
|
Ultra-Efficient Nucleic Acid Synthesis & Automated Synthesizer
|
Discovery
|
Automated synthesizer based on immersion-type solid-phase synthesis.
|
Complete prototype, validate reagent savings, and explore partnerships with CDMOs and equipment manufacturers.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
Seed Round Financing (Jan, 2024): Raised approx. JPY 150 million from Real Tech Fund and Mitsubishi Gas Chemical.
NEDO STS Grant (2023–2024): “Automation of Ultra-Efficient Nucleic Acid Synthesis Method” with a grant of JPY 80 million.
Selected for Rising Biotech Challenge 2025: Plug and Play Japan × Tokyo Metropolitan Government accelerator program
|
|
Alliance strategy
|
Drug Discovery: Co-development for preclinical studies, licensing discussions, translational research support.
Synthesis Technology: Joint development with CDMOs and equipment manufacturers, PoC sites for automated synthesizer.
Funding: Preparing for next round (Seed extension to Pre-A) with strategic investors and VCs.
|
|
|